Determinants of Vaccination Coverage Against Human Papillomavirus in 10-year-old Girls in 2016 in Rural Senegal
Science Journal of Public Health
Volume 5, Issue 6, November 2017, Pages: 464-468
Received: Sep. 16, 2017; Accepted: Oct. 11, 2017; Published: Nov. 24, 2017
Views 579      Downloads 24
Authors
Adama Faye, Department of Preventive Medicine and Public Health, Cheikh Anta Diop University, Dakar, Senegal
Sidy Ndiaye, Ministry of Health and Social Action, Dakar, Senegal
Khadim Niang, Department of Preventive Medicine and Public Health, Cheikh Anta Diop University, Dakar, Senegal
Mamadou Ndiaye, Ministry of Health and Social Action, Dakar, Senegal
Anta Tal-Dia, Department of Preventive Medicine and Public Health, Cheikh Anta Diop University, Dakar, Senegal
Article Tools
Follow on us
Abstract
Cervical cancer is the first gynecological cancer in Senegal. As part of the cancer control plan, the Ministry of Health and Social Action conducted a pilot phase of HPV vaccination in the districts of Dakar and Mekhe between 2014 and 2016. The objective of this survey is to study the determinants of HPV vaccination coverage in 10-year-old girls in 2016 in the Mekhe health district. This is a descriptive cross-sectional epidemiological study for analytical purposes. A two-stage survey was conducted. The data were collected during an individual interview at the homes of the mothers. The compendium focused on personal characteristics, knowledge and practices on immunization. Full vaccination coverage was determined. Logistic regression was used to identify factors associated with immunization coverage. Respondents were 300 The mean age was 35 ± 9.64 years. Mothers who knew how to prevent cervical cancer were 171 or 57% [95% CI: 51.2-62.7]. Immunization coverage for girls aged 10 years was 86.3% [95% CI: 81.9-90.0]. The discontinuation between the first and second dose of the vaccine was 6.5% [95% CI: 3.9-10.1]. HPV vaccine coverage was related to the residence environment (OR = 3, 18 [95% CI: 1.34-7.56]); (OR = 22.02, [95% CI: 4.2-113.4]) and information for mothers (OR = 10.92 [95% CI: 2.93-40.64]). Vaccination against HPV is a preventive activity that requires the collaboration with the education sector and a good proximity communication.
Keywords
Immunization Coverage, HPV, Girl, Determinants, Senegal
To cite this article
Adama Faye, Sidy Ndiaye, Khadim Niang, Mamadou Ndiaye, Anta Tal-Dia, Determinants of Vaccination Coverage Against Human Papillomavirus in 10-year-old Girls in 2016 in Rural Senegal, Science Journal of Public Health. Vol. 5, No. 6, 2017, pp. 464-468. doi: 10.11648/j.sjph.20170506.19
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-386.
[2]
De Vuyst H, Alemany L, Lacey C, Chibwesha CJ, Sahasrabuddhe V, Banura C, Denny L, Parham GP. The burden of human papillomavirus infections and related diseases in sub-saharan Africa. Vaccine. 2013 Dec 29; 31 Suppl 5: F32-46.
[3]
Touré P, Ahmadou Dem B, Traoré MM, Dieng PS, Diop T, Ouajdi MT, et al. Gynecological and mammary cancers at the Dakar Cancer Institute. Cahiers Santé 2008. (18).
[4]
Mboumba Bouassa RS, Prazuck T, Lethu T, Jenabian MA, Meye JF, Bélec L. Cervical cancer in sub-Saharan Africa: a preventable non-communicable disease. Expert Rev Anti Infect Ther. 2017 Jun; 15(6): 613-627.
[5]
Lamontagne DS, Barge S, Nga TL, Mugisha E, and all. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011; 89: 821-830.
[6]
Odusanya OO, Alufohai EF, Meurice PF, Ahonkha VI. Determinants of vaccination coverage in rural Nigeria. BMC Public Health 2008, 8: 381.
[7]
Vermandere H, Violet NV, Mabeya H and al.; Determinants of acceptance and subsequent uptake of the HPV vaccine in a cohort in Eldoret, kenya. plos one 9(10): e109353. doi: 10.1371.
[8]
Poole DN, Tracy JK, Levitz L, Rochas M, Sangare K, et al. A cross-sectional study to assess HPV knowledge and HPV vaccine acceptability in Mali. Plos one 8(2): e56402. Doi: 10. 1371.
[9]
Hosmer DW, Lemeshow S. Applied Logistic Regression. New York: Wiley-Interscience; 2007.
[10]
Ladner J, Besson MH, Rodrigues M et al. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009–2014. BMJ Health services research. 2016, 16: 575.
[11]
Binagwaho A, Wagner CM, Gatera M, and all. Achieving high coverage in Rwanda’s national human papillomavirus vaccination program bull world health organ. 2012; 90: 623–628.
[12]
Deborah WJ, Baisley K, and all. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies PLoS ONE 10(6): e0123701. doi: 10.1371.
ADDRESS
Science Publishing Group
548 FASHION AVENUE
NEW YORK, NY 10018
U.S.A.
Tel: (001)347-688-8931